ReviewTherapeutic advances in neurological disorders2020
The role of erenumab in the treatment of migraine.
Review in Therapeutic advances in neurological disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Bridging the gap: molecular mechanisms, regional activity and connectivity in headache disorders.Brain : a journal of neurology · 2026Review
- Current Trends in Management of Migraine: A Review of Current Practice and Recent Advances.CNS & neurological disorders drug targets · 2026Review
- Sex differences in the effects of calcitonin gene-related peptide signaling on migraine-like behavior in animal models: a narrative review.Frontiers in neurology · 2025Review
- Article
- Exploring Erenumab's Efficacy and Safety for Migraine Prevention in Real-World Settings: A Systematic Review.Cureus · 2024Review
- Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS pharmacology & translational science · 2024Review
- Reporting Quality and Risk of Bias Analysis of Published RCTs Assessing Anti-CGRP Monoclonal Antibodies in Migraine Prophylaxis: A Systematic Review.Journal of clinical medicine · 2024Review
- Intelligent Digital Twins for Personalized Migraine Care.Journal of personalized medicine · 2023Review
- Excitation-Inhibition Imbalance in Migraine: From Neurotransmitters to Brain Oscillations.International journal of molecular sciences · 2023Review
- The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.The journal of headache and pain · 2023Article
- Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?Medicina (Kaunas, Lithuania) · 2023Article
- Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis.The journal of headache and pain · 2022Article
- Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics.Pharmacological reviews · 2022Review
- Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.BMC neurology · 2022Observational
- Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis.The journal of headache and pain · 2022Article
- Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine's Prophylaxis.Journal of clinical medicine · 2021Article
- Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine.Frontiers in neurology · 2021Article
- Review
- Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.Saudi journal of medicine & medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of migraine symptoms, migraine-specific quality of life and headache related disability. Treatment-related side effects overall did not differ significantly from placebo and discontinuation rate due to side effects has been low across the clinical trials, perhaps in view of their peripheral mode of action. Along with their route and frequency of administration, these novel class of drugs may constitute an improvement compared with the established arsenal of migraine treatments. Erenumab is a fully human antibody and the only mAb acting on the CGRP pathway by blocking its receptor. It is the first of the CGRP mAb class approved by the US Food and Drug Administration (May 2018) and the European Medicines Agency (July 2018). Erenumab exists in two different doses (70 mg and 140 mg) and it is administered with monthly subcutaneous injections. This review summarises erenumab pharmacological characteristics, clinical trials data, focusing on the potential role of this treatment in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.